Sodium zirconium cyclosilicate (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sodium zirconium cyclosilicate" in English language version.

refsWebsite

Global rank English rank

15nih.gov

4^th place

8doi.org

2^nd place

7web.archive.org

1^st place

2drugs.com

399^th place

333^rd place

1tga.gov.au

3,984^th place

2,622^nd place

1hres.ca

low place

1europa.eu

68^th place

117^th place

1fda.gov

447^th place

338^th place

1harvard.edu

18^th place

17^th place

1semanticscholar.org

11^th place

8^th place

1fiercebiotech.com

low place

8,828^th place

doi.org

Hoy SM (October 2018). "Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia". Drugs. 78 (15): 1605–1613. doi:10.1007/s40265-018-0991-6. PMC 6433811. PMID 30306338.
Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS (2014). "Characterization of structure and function of ZS-9, a K+ selective ion trap". PLOS ONE. 9 (12): e114686. Bibcode:2014PLoSO...9k4686S. doi:10.1371/journal.pone.0114686. PMC 4273971. PMID 25531770.
Kovesdy CP (March 2017). "Updates in hyperkalemia: Outcomes and therapeutic strategies". Reviews in Endocrine & Metabolic Disorders. 18 (1): 41–47. doi:10.1007/s11154-016-9384-x. PMC 5339065. PMID 27600582.
McDonald TJ, Oram RA, Vaidya B (October 2015). "Investigating hyperkalaemia in adults". BMJ. 351: h4762. doi:10.1136/bmj.h4762. PMID 26487322. S2CID 206907572.
Lehnhardt A, Kemper MJ (March 2011). "Pathogenesis, diagnosis and management of hyperkalemia". Pediatric Nephrology. 26 (3): 377–84. doi:10.1007/s00467-010-1699-3. PMC 3061004. PMID 21181208.
Watson M, Abbott KC, Yuan CM (October 2010). "Damned if you do, damned if you don't: potassium binding resins in hyperkalemia". Clinical Journal of the American Society of Nephrology. 5 (10): 1723–6. doi:10.2215/CJN.03700410. PMID 20798253.
Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR (October 2010). "Management of patients with acute hyperkalemia". CMAJ. 182 (15): 1631–5. doi:10.1503/cmaj.100461. PMC 2952010. PMID 20855477.
Meaney CJ, Beccari MV, Yang Y, Zhao J (April 2017). "Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia". Pharmacotherapy. 37 (4): 401–411. doi:10.1002/phar.1906. PMC 5388568. PMID 28122118.

drugs.com

"Sodium Zirconium Cyclosilicate Monograph for Professionals". Drugs.com. Archived from the original on 1 August 2020. Retrieved 11 October 2019.
"Lokelma (Sodium zirconium cyclosilicate) FDA Approval History". Archived from the original on 12 June 2018. Retrieved 11 June 2018.

europa.eu

ema.europa.eu

"Lokelma EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 January 2021. Retrieved 11 October 2019.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Lokelma (sodium zirconium cyclosilicate)". U.S. Food and Drug Administration (FDA). 8 June 2018. Archived from the original on 13 April 2021. Retrieved 7 May 2020.

fiercebiotech.com

Ben Adams (27 May 2016). "AstraZeneca's $2.7B hyperkalemia drug ZS-9 rejected by FDA". FierceBiotech. Archived from the original on 28 May 2016. Retrieved 27 May 2016.

harvard.edu

ui.adsabs.harvard.edu

Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS (2014). "Characterization of structure and function of ZS-9, a K+ selective ion trap". PLOS ONE. 9 (12): e114686. Bibcode:2014PLoSO...9k4686S. doi:10.1371/journal.pone.0114686. PMC 4273971. PMID 25531770.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Lokelma". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hoy SM (October 2018). "Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia". Drugs. 78 (15): 1605–1613. doi:10.1007/s40265-018-0991-6. PMC 6433811. PMID 30306338.
Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS (2014). "Characterization of structure and function of ZS-9, a K+ selective ion trap". PLOS ONE. 9 (12): e114686. Bibcode:2014PLoSO...9k4686S. doi:10.1371/journal.pone.0114686. PMC 4273971. PMID 25531770.
Kovesdy CP (March 2017). "Updates in hyperkalemia: Outcomes and therapeutic strategies". Reviews in Endocrine & Metabolic Disorders. 18 (1): 41–47. doi:10.1007/s11154-016-9384-x. PMC 5339065. PMID 27600582.
McDonald TJ, Oram RA, Vaidya B (October 2015). "Investigating hyperkalaemia in adults". BMJ. 351: h4762. doi:10.1136/bmj.h4762. PMID 26487322. S2CID 206907572.
Lehnhardt A, Kemper MJ (March 2011). "Pathogenesis, diagnosis and management of hyperkalemia". Pediatric Nephrology. 26 (3): 377–84. doi:10.1007/s00467-010-1699-3. PMC 3061004. PMID 21181208.
Watson M, Abbott KC, Yuan CM (October 2010). "Damned if you do, damned if you don't: potassium binding resins in hyperkalemia". Clinical Journal of the American Society of Nephrology. 5 (10): 1723–6. doi:10.2215/CJN.03700410. PMID 20798253.
Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR (October 2010). "Management of patients with acute hyperkalemia". CMAJ. 182 (15): 1631–5. doi:10.1503/cmaj.100461. PMC 2952010. PMID 20855477.
Meaney CJ, Beccari MV, Yang Y, Zhao J (April 2017). "Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia". Pharmacotherapy. 37 (4): 401–411. doi:10.1002/phar.1906. PMC 5388568. PMID 28122118.

ncbi.nlm.nih.gov

Hoy SM (October 2018). "Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia". Drugs. 78 (15): 1605–1613. doi:10.1007/s40265-018-0991-6. PMC 6433811. PMID 30306338.
Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS (2014). "Characterization of structure and function of ZS-9, a K+ selective ion trap". PLOS ONE. 9 (12): e114686. Bibcode:2014PLoSO...9k4686S. doi:10.1371/journal.pone.0114686. PMC 4273971. PMID 25531770.
Kovesdy CP (March 2017). "Updates in hyperkalemia: Outcomes and therapeutic strategies". Reviews in Endocrine & Metabolic Disorders. 18 (1): 41–47. doi:10.1007/s11154-016-9384-x. PMC 5339065. PMID 27600582.
Lehnhardt A, Kemper MJ (March 2011). "Pathogenesis, diagnosis and management of hyperkalemia". Pediatric Nephrology. 26 (3): 377–84. doi:10.1007/s00467-010-1699-3. PMC 3061004. PMID 21181208.
Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR (October 2010). "Management of patients with acute hyperkalemia". CMAJ. 182 (15): 1631–5. doi:10.1503/cmaj.100461. PMC 2952010. PMID 20855477.
Meaney CJ, Beccari MV, Yang Y, Zhao J (April 2017). "Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia". Pharmacotherapy. 37 (4): 401–411. doi:10.1002/phar.1906. PMC 5388568. PMID 28122118.

dailymed.nlm.nih.gov

"Lokelma- sodium zirconium cyclosilicate powder, for suspension". DailyMed. 30 September 2022. Archived from the original on 5 December 2022. Retrieved 27 February 2023.

semanticscholar.org

api.semanticscholar.org

McDonald TJ, Oram RA, Vaidya B (October 2015). "Investigating hyperkalaemia in adults". BMJ. 351: h4762. doi:10.1136/bmj.h4762. PMID 26487322. S2CID 206907572.

tga.gov.au

"Lokelma APMDS". Therapeutic Goods Administration (TGA). 24 May 2024. Retrieved 10 June 2024.

web.archive.org

"Summary Basis of Decision (SBD) for Lokelma". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
"Lokelma- sodium zirconium cyclosilicate powder, for suspension". DailyMed. 30 September 2022. Archived from the original on 5 December 2022. Retrieved 27 February 2023.
"Lokelma EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 January 2021. Retrieved 11 October 2019.
"Sodium Zirconium Cyclosilicate Monograph for Professionals". Drugs.com. Archived from the original on 1 August 2020. Retrieved 11 October 2019.
"Drug Approval Package: Lokelma (sodium zirconium cyclosilicate)". U.S. Food and Drug Administration (FDA). 8 June 2018. Archived from the original on 13 April 2021. Retrieved 7 May 2020.
Ben Adams (27 May 2016). "AstraZeneca's $2.7B hyperkalemia drug ZS-9 rejected by FDA". FierceBiotech. Archived from the original on 28 May 2016. Retrieved 27 May 2016.
"Lokelma (Sodium zirconium cyclosilicate) FDA Approval History". Archived from the original on 12 June 2018. Retrieved 11 June 2018.